![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of the efficacy and tolerability
of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study
|
|
|
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Stefan Zeuzem,1 Stefan Bourgeois,2 Susan Greenbloom,3 Maria Buti,4
Alessio Aghemo,5 Ewa Janczewska,6 Seng Gee Lim,7 Chris Corbett,8
Wouter Willems,8 Leen Vijgen,8 Sivi Ouwerkerk-Mahadevan,8
Maria Beumont,8 Rekha Sinha,9 Ronald Kalmeijer,9 Michael Biermer8
1JW Goethe University, Frankfurt am Main, Germany; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Toronto Digestive Disease Associates, Inc., Vaughan, ON, Canada; 4Hospital Vall d'Hebron and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 5Humanitas University, Rozzano, Italy; 6Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland; 7National University Hospital, Singapore; 8Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium;
9Janssen Research & Development, LLC, Titusville, NJ, USA
![1023171](../images/102317/102317-18/1023171.gif)
![1023172](../images/102317/102317-18/1023172.gif)
![1023173](../images/102317/102317-18/1023173.gif)
![1023174](../images/102317/102317-18/1023174.gif)
![1023175](../images/102317/102317-18/1023175.gif)
![1023176](../images/102317/102317-18/1023176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|